Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
- Symbol
- CAI
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $8.94B
- 52 week range
- 14.19 - 33.65
Valuation
- Share price
- $31.53 (close of 2026-09-23)
- P/E (TTM)
- 3.81x
- Price to book
- 15.11x
- Price to free cash flow
- 72.15x
- Enterprise value
- $9.40B
- Book value per share
- $2.09
Price performance
| Period | Change |
|---|
| 1 day | +2.87% |
| 5 days | +10.63% |
| 1 month | +20.02% |
| 3 months | +79.15% |
| 6 months | +63.71% |
| Year to date | +16.86% |
| 1 year | -1.78% |
| All time | +12.61% |
Profitability and growth
- Return on equity
- -11.79%
- Return on invested capital
- 21.61%
- Return on assets
- -6.05%
- Return on capital employed
- 4.52%
- Gross margin
- 66.40%
- Net margin
- -8.38%
- EBITDA margin
- 8.34%
- Revenue growth
- 96.97%
- Net income growth
- 75.85%
- Free cash flow growth
- 126.37%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 1.39%
- Current ratio
- 5.53x
- Net debt to EBITDA
- 2.62x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $812.03M
- Cost of revenue
- $272.87M
- Gross profit
- $539.17M
- EBITDA
- $67.73M
- Net income
- $-68.09M
- Earnings per share
- $-3.22
- Research and development
- $101.58M
- Shares outstanding
- 167.21M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $812.03M | $539.17M | $-68.09M | $-3.22 |
| 2024-12-31 | $412.26M | $178.78M | $-281.89M | $-10.66 |
| 2023-12-31 | $306.13M | $89.31M | $-341.42M | $-13.24 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 66.40% | -8.38% | -11.79% | 21.61% |
| 2024-12-31 | 43.37% | -68.38% | 11.28% | - |
| 2023-12-31 | 29.17% | -111.53% | 15.92% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $796.27M | $378.82M |
| 2024-12-31 | $63.95M | $319.44M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $66.89M | $70.01M |
| 2024-12-31 | $-253.64M | $18.64M |
| 2023-12-31 | $-298.42M | $15.24M |
Dividend history
- Most recent payment
- 2021-09-09
| Payment date | Dividend per share |
|---|
| 2021-09-09 | $0.30 |
| 2021-06-09 | $0.30 |
| 2021-03-10 | $0.30 |
| 2020-12-08 | $0.25 |
| 2020-09-10 | $0.25 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.03
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | - |
| 2026-05-07 | - | - |
| 2026-02-26 | - | - |
| 2025-11-05 | - | - |
| 2025-08-12 | - | - |
| 2021-11-05 | - | - |
| 2021-08-03 | - | - |
| 2021-04-29 | - | - |
Filings and sources
- Company website
- carislifesciences.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades